1
Home
Companies

BioVie

BioVie
Leadership team

Mr. Cuong Viet Do M.B.A., MBA (Pres, CEO & Director)

Ms. Joanne Wendy Kim CPA (CFO, Treasurer & Corp. Sec.)

Dr. Joseph M. Palumbo M.D. (Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Innovation Management, Therapeutics, Wellness
Number of Employees
0 - 50
Headquarters
Beverly, Massachusetts, United States
Established
2013
Company Registration
SEC CIK number: 0001580149
Traded as
NASDAQ:BIVI
URL
https://bioviepharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
History

BioVie was founded in 2018 in Houston, Texas. The company's founders have decades of experience in biotechnology and drug development, and have brought together a team of scientists and executives with a shared vision for a new approach to drug therapy for liver disease.

Mission
Our mission is to discover and develop new therapies that improve the lives of people living with liver diseases.
Vision
Our vision is to become the leading biopharmaceutical company in the development of innovative therapies for liver diseases.
Key Team

Dr. Christopher L. Reading Ph.D. (Exec. VP of Neuroscience R&D)

Mr. Clarence N. Ahlem (Exec. VP of Neuroscience Product Devel.)

Ms. Sarah Overton Hoit (Chief Social Impact Officer)

Dr. Penelope Markham Ph.D. (Exec. VP of Liver Disease R&D)

Ms. Denise Smith (Sr. VP of Manufacturing & Devel.)

Recognition and Awards
BioVie is the proud recipient of the American Liver Foundation's top award for innovation in drug development. The award recognizes BioVie's commitment to advancing new therapies and treatments for liver diseases.
References

https://in.investing.com/equities/biovie-inc

https://finance.yahoo.com/quote/BIVI/profile?p=BIVI

https://www.crunchbase.com/organization/biovie

https://bioviepharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

BioVie
Leadership team

Mr. Cuong Viet Do M.B.A., MBA (Pres, CEO & Director)

Ms. Joanne Wendy Kim CPA (CFO, Treasurer & Corp. Sec.)

Dr. Joseph M. Palumbo M.D. (Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Innovation Management, Therapeutics, Wellness
Number of Employees
0 - 50
Headquarters
Beverly, Massachusetts, United States
Established
2013
Company Registration
SEC CIK number: 0001580149
Traded as
NASDAQ:BIVI
URL
https://bioviepharma.com